Greenbackd

9 Comments »

9 Responses

1. on December 22, 2009 at 3:27 pm | Reply steve

   You guys ever take a look at Insmed INSM.Think it fits your parameters.Think you were a little late on CNVR.It was a buy sub .20 and a sell north of .25.Mgmt gets a nice half mill bonus if deal closes.I have spoken to CFO and the deal should have been consumated in August.Losing credibility with me as the cash burn clock keeps ticking.

   
   
2. on November 3, 2009 at 1:13 pm | Reply Joe G

   ….what is your view on Aspen’s news release today concerning a dividend payout of .73 per share.I’m holding a few thousand shares and wonder if I should hold after the dividend….joe g

   http://www.marketwire.com/press-release/Aspen-Exploration-Corporation-1070024.html

   Nov 03, 2009 10:00 ETAspen Exploration Corporation Announces DividendDENVER, CO–(Marketwire – November 3, 2009) – Aspen Exploration Corporation (OTCBB: ASPN) announced today that the Aspen board of directors has determined the amount of the distribution to be paid to stockholders from the proceeds of the sale of its California oil and gas assets to Venoco, Inc. A cash dividend of $0.73 per share will be payable to stockholders of record on November 16, 2009, with the dividend being paid on or about December 2, 2009. This announcement follows the final settlement of the sale of Aspen’s California oil and gas assets to Venoco, Inc. Aspen previously announced its intention to distribute to its stockholders substantially all of the net, after-tax proceeds from the completion of the sale of its assets to Venoco, but needed to complete certain calculations before it was able to determine the dollar amount of the assets to be distributed.

   For more information, contact R. V. Bailey, CEO, in Aspen’s Denver office at 303-639-9860.

   DISCLAIMER

   This news release contains information that is “forward-looking” in that it describes events and conditions, which Aspen Exploration Corporation (“Aspen”) reasonably expects to occur in the future. Expectations for the future performance of the business of Aspen are dependent upon a number of factors, and there can be no assurance that Aspen will achieve the results as contemplated herein and there can be no assurance that Aspen will be able to conduct its operations as contemplated herein. Certain statements contained in this release using the terms “may,” “expects to,” and other terms denoting future possibilities, are forward-looking statements. The accuracy of these statements cannot be guaranteed as they are subject to a variety of risks, which are beyond Aspen’s ability to predict, or control and which may cause actual results to differ materially from the projections or estimates contained herein. Aspen’s operations are subject to a number of risks, many of which are described in Aspen’s annual report on Form 10-K, and it is important that each person reviewing this release understand the significant risks attendant to the operations of Aspen. Aspen disclaims any obligation to update any forward-looking statement made herein.

   ASPEN EXPLORATION CORPORATION
   2050 S. Oneida St., Ste. 208
   Denver, CO 80224-2426
   Telephone: (303) 639-9860
   Fax: (303) 639-9863
   Email: aecorp2@qwestoffice.net
   Web Site: http://www.aspenexploration.com
   Contact:
   R.V. Bailey
   CEO
   303-639-9860
   aecorp2@qwestoffice.net Click here to see all recent news from this company

   
   
   • on November 3, 2009 at 7:21 pm | Reply greenbackd

     Joe G,

     See tomorrow night’s post.

     G

     
     
3. on June 16, 2009 at 1:35 pm | Reply ValueSeeker

   Congratulations on Soapstone. Do you guys have any of Mark McGowan’s letters to the Soapstone Board? I know his SAF fund was pushing them to sell or liquidate, I’d love to see those letters!

   
   
   • on June 16, 2009 at 3:25 pm | Reply greenbackd

     Thanks, ValueSeeker.

     
     
4. on May 6, 2009 at 7:11 pm | Reply rolandx

   Congrats on your Vanda, up 900% tonight at an even $10. Drug approved and could be heading to the $30 IPO or higher. Your entry was 0.78, WOW.
   Antipsychotic with a much better side effect profile than some leading drugs now on the market.

   
   
   • on May 6, 2009 at 7:35 pm | Reply greenbackd

     Thanks, rolandx. In this instance, we were right for the wrong reasons (but we’ll still take the money).

     G

     
     
5. on March 6, 2009 at 10:10 am | Reply ef

   The portfolio could also be tracked and the returns compared with professional investors at http://www.tickerspy.com

   
   
   • on March 6, 2009 at 7:53 pm | Reply greenbackd

     ef, we’re testing out the tickerspy site. You can see our portfolio here.